Tunisia
Tuberculosis profile
Population  2013 11 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.23 (0.085–0.42) 2.1 (0.78–3.8)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.02 (0.01–0.03)
Prevalence  (includes HIV+TB) 4.2 (1.5–8.1) 38 (14–73)
Incidence  (includes HIV+TB) 3.5 (3.2–3.8) 32 (29–34)
Incidence (HIV+TB only) 0.015 (0.013–0.016) 0.14 (0.12–0.15)
Case detection, all forms (%) 87 (81–96)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 0.8 (0–1.7) 12 (4.5–19)
MDR-TB cases among notified pulmonary
TB cases
10 (0–21) 10 (4–17)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 1 003   54
Pulmonary, clinically diagnosed 212    
Extrapulmonary 1 766    
       
Total new and relapse 3 035    
Previously treated, excluding relapses 35    
Total cases notified 3 070    
Among 3 035 new and relapse cases:
196 (6%) cases aged under 15 years; male:female ratio: 1.0
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 730 (73%) 53 (60%) 783
Laboratory-confirmed RR-/MDR-TB cases     17
Patients started on MDR-TB treatment     14
TB/HIV 2013 Number (%)
TB patients with known HIV status 783 (26)
HIV-positive TB patients 17 (2)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART) 17 (100)
HIV-positive people screened for TB    
HIV-positive people provided with IPT 53  
Treatment success rate (%)
New cases registered in 2012 89
Previously treated cases registered in 2012 88
HIV-positive TB cases, all types, registered in 2012 93
RR-/MDR-TB cases started on second-line treatment in 2011 75
XDR-TB cases started on second-line treatment in 2011 0
Laboratories 2013  
Smear (per 100 000 population) 0.7
Culture (per 5 million population) 5.0
Drug susceptibility testing (per 5 million population) 2.3
Sites performing Xpert MTB/RIF 2
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) 1.3
% Funded domestically 45%
% Funded internationally 55%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-08-02 Data: www.who.int/tb/data